Kailera Therapeutics (KLRA) CMO reports sizable stock option positions

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Kailera Therapeutics, Inc. filed an initial ownership report for Chief Medical Officer Scott M. Wasserman, showing existing stock option holdings in the company. These options give him the right to buy common shares at exercise prices of $7.24 and $5.25 per share, with expirations in 2034 and 2035. The footnotes explain that each grant vests 25% on an initial vesting date in 2025 or 2026, then in 36 substantially equal monthly installments, conditioned on his continued service.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Wasserman Scott M.

Role Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 287,166 shares (Direct, null)

Footnotes (1)

The options vested and became exercisable as to 25% of the total shares on December 9, 2025 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date. The options vested and became exercisable as to 25% of the total shares on September 30, 2025 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date. The options vest and become exercisable as to 25% of the total shares on November 5, 2026 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Underlying shares grant 1: 147,324 shares Underlying shares grant 2: 427,960 shares Underlying shares grant 3: 287,166 shares +5 more

8 metrics

Underlying shares grant 1 147,324 shares Stock Option, exercise price $7.24

Underlying shares grant 2 427,960 shares Stock Option, exercise price $5.25

Underlying shares grant 3 287,166 shares Stock Option, exercise price $5.25

Exercise price (higher grant) $7.24/share Stock Option expiring November 5, 2035

Exercise price (two grants) $5.25/share Stock Options expiring December 9, 2034

Option expiration 1 December 9, 2034 Stock Option (right to buy), $5.25 exercise

Option expiration 2 November 5, 2035 Stock Option (right to buy), $7.24 exercise

Initial vesting dates Sept 30 & Dec 9, 2025; Nov 5, 2026 25% of option shares vest on each initial date

Key Terms

Stock Option (right to buy), Common Stock, vested and became exercisable, substantially equal monthly installments, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vested and became exercisable financial

"The options vested and became exercisable as to 25% of the total shares"

substantially equal monthly installments financial

"thereafter in 36 substantially equal monthly installments"

continued service financial

"subject to the Reporting Person's continued service on each such vesting date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding Insider Trading Forms →

04/16/2026 - 07:45 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wasserman Scott M.

(Last)

(First)

(Middle)

C/O KAILERA THERAPEUTICS, INC.

180 THIRD AVENUE, 4TH FLOOR

(Street)

WALTHAM

MASSACHUSETTS

02451

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/16/2026

3. Issuer Name and Ticker or Trading Symbol
Kailera Therapeutics, Inc. [ KLRA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	12/09/2034	Common Stock	287,166	$5.25	D
Stock Option (right to buy)	⁽²⁾	12/09/2034	Common Stock	427,960	$5.25	D
Stock Option (right to buy)	⁽³⁾	11/05/2035	Common Stock	147,324	$7.24	D

Explanation of Responses:

1. The options vested and became exercisable as to 25% of the total shares on December 9, 2025 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.

2. The options vested and became exercisable as to 25% of the total shares on September 30, 2025 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.

3. The options vest and become exercisable as to 25% of the total shares on November 5, 2026 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ John Mei, Attorney-in-fact	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does the KLRA Form 3 filing show for Scott M. Wasserman?

The Form 3 shows Chief Medical Officer Scott M. Wasserman’s existing stock option holdings in Kailera Therapeutics. It details option strike prices, expiration dates, and vesting schedules tied to his continued service with the company.

How many KLRA common shares are underlying Scott Wasserman’s options?

Scott Wasserman holds stock options over 147,324, 427,960, and 287,166 underlying Kailera common shares in three separate grants. Each grant is subject to its own vesting schedule as described in the footnotes to the ownership report.

What are the exercise prices of Scott Wasserman’s KLRA stock options?

His reported stock options have exercise prices of $7.24 and $5.25 per share. These prices are fixed in the grants and represent the cost per share if he chooses to exercise the options in the future.

When do Scott Wasserman’s KLRA stock options expire?

The reported stock options expire on December 9, 2034 and November 5, 2035, depending on the grant. He generally must exercise vested portions before these expiration dates for the options to retain their economic value.

How do Scott Wasserman’s KLRA options vest over time?

Each option grant vests 25% on an initial date in 2025 or 2026, then in 36 substantially equal monthly installments. Vesting continues only while Scott Wasserman remains in service with Kailera Therapeutics on each scheduled vesting date.

Does the KLRA Form 3 indicate any recent insider buying or selling?

The filing lists existing stock option holdings rather than new purchases or sales. Transactions are coded as holdings with unknown transaction codes, so it functions mainly as an initial ownership snapshot for the Chief Medical Officer.